Context

Chronic antibody-mediated rejection (cABMR) is considered one of the main causes of chronic graft.

Objective

To review the mechanisms that cause cABMR to design effective treatments, since it is very little what has been advanced in it treatment of this pathology.

Methodology

In this narrative review of the literature, we present the risk factors related to the chronic dysfunction of the injection, emphasizing the pathophysiology the diagnosis and treatment of cABMR.

Results

The most relevant risk factor for the development of chronic graft dysfunction is the development of specific donor antibodies (DSA) and ABMR. For the diagnosis of active cABMR, the criteria of Banff 2017 are required (three must be present: histological evidence of chronic tissue injury, evidence of current inflammation in the vascular endothelium caused by antibodies and serological evidence of DSA. The cABMR does not have an effective treatment.

Conclusions

Since cABMR does not have an effective treatment, it is important reduce exposure to risk factors and carry out a diagnosis and treatment of the acute events of kidney injury that contribute to the progression of chronic injection dysfunction.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )